New Delhi January 10, 2014: Ranbaxy Laboratories on Thursday inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab prescribed to treat rheumatoid arthritis (RA).
EPIRUS Switzerland GmbH is a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, Inc.
The product will be introduced in India and other Emerging Markets, the company said in a statement.
At present, there is no biosimilar of Infliximab approved in India, it said.
Under the terms of the agreement, EPIRUS will develop and supply the product; and upon regulatory approval, Ranbaxy will market the same in India and other emerging markets.
Commenting on the partnership, Sanjeev I Dani, Executive Vice President & Head, Global Strategy, Ranbaxy, said, “We will utilise our strong front-end capabilities in making this product available in India and other parts of the world.”
Amit Munshi, President and CEO of EPIRUS said: “We are very pleased to work with Ranbaxy to register and commercialise this important medicine. Ranbaxy has the right focus and infrastructure in these markets to effectively bring this product to the market.” -Business Today
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…